Financial Performance - Full-year 2024 total revenues reached $58.38 million, representing a 23.5% increase from 2023[3] - Full-year 2024 net income was $3.82 million, or diluted earnings per share of $0.07, down from $6.46 million, or $0.12 per share in 2023[3] - Full-year 2024 Adjusted EBITDA increased by 43.3% to $9.62 million, with diluted Adjusted EBITDA per share at $0.17 compared to $0.12 in 2023[3] - Fourth quarter 2024 total revenues were $15.61 million, up 14.0% from the same quarter in 2023[8] - Fourth quarter 2024 net income was $1.37 million, or diluted earnings per share of $0.02, down from $5.62 million, or $0.10 per share in Q4 2023[8] - Fourth quarter 2024 Adjusted EBITDA was $2.86 million, a 14.3% increase from $2.51 million in Q4 2023[8] - For full-year 2025, total revenues are expected to be between $68.5 million and $70.0 million, representing year-over-year growth of 17.5% to 20.0%[15] - Net income for full-year 2025 is expected to be approximately break-even, or $0.00 per diluted share[15] - For the year ended December 31, 2024, net income was $1,372,872, a decrease from $5,622,409 in 2023[30] - Adjusted EBITDA for the year ended December 31, 2024, was $9,621,083, up from $6,712,966 in 2023, representing a 43.5% increase[30] - The company reported a net income margin of 6.5% for 2024, down from 13.7% in 2023[32] Revenue Sources - Patient affordability revenue surged by 214.5% to $8.63 million, contributing 21.7% of total revenue in 2024, expected to rise to over 37.0% in 2025[7][14] - Plasma revenue is projected to account for approximately 57.5% of total revenue, while pharma revenue is expected to grow at least 100% year-over-year[15] Operational Metrics - The total plasma center count increased by 16 to 480 centers, leading to a 4.6% increase in plasma revenue[3] - The company added 16 net plasma donation centers, ending the year with a total of 480 centers, and added 33 net pharma patient affordability programs, bringing the total to 76 active programs[16] Future Projections - For Q1 2025, total revenue is expected to be between $17.5 million and $18.0 million, with gross profit margins projected at 63.0% to 64.0%[15] - Full-year gross profit margins for 2025 are anticipated to be between 62.0% and 64.0%[15] - Operating expenses for 2025 are expected to be between $47.5 million and $50.0 million, including costs related to a recent acquisition[15] - Adjusted EBITDA for full-year 2025 is projected to be in the range of $12.5 million to $13.5 million, or $0.22 to $0.24 per diluted share[15] Cash and Debt Management - The company exited 2024 with $10.77 million in unrestricted cash and zero debt, having repurchased 136,700 shares for $495 thousand[3] - Restricted cash balances increased by 20.8% from December 31, 2023, to $111.58 million, primarily due to growth in customer programs[16] - The company expects to generate interest income of approximately $2.8 million in 2025[15] Cost and Expense Analysis - Stock-based compensation expense was $2,604,589 for the year ended December 31, 2024, down from $2,853,643 in 2023[30] - The income tax provision for 2024 was a benefit of $(137,265), compared to a benefit of $(4,259,730) in 2023[30] - Interest income, net, was $(3,116,689) for 2024, compared to $(2,531,071) in 2023[30] EBITDA and Margins - The Adjusted EBITDA margin improved to 16.5% in 2024 from 14.2% in 2023[32] - The EBITDA margin also increased to 12.0% in 2024 compared to 8.2% in 2023[32] - Basic Adjusted EBITDA per share remained stable at $0.05 for both 2024 and 2023[30] - The weighted average common shares for diluted calculations were 55,527,689 in 2024, compared to 53,773,758 in 2023[30]

Group 1 - Paysign, Inc. operates in the healthcare-focused Fintech sector and has made significant inroads into the estimated $500 million Patient Affordability market [1] - The company has achieved an impressive average revenue growth of 230% over the past four quarters specifically in its Pharma segment [1] - Despite being a small company, Paysign, Inc. has demonstrated strong performance metrics that may indicate potential investment opportunities [1]

Core Insights - Paysign (NASDAQ: PAYS) is identified as a U.S. microcap payment processing business that has been closely monitored for over a decade [1] Company Overview - The company has experienced significant stock movement, with a notable increase of approximately 12 times since May 2018 [1]

Revenue Growth - Total revenues for the three months ended September 30, 2024, increased by $2,856,106, or 23.0%, compared to the same period in 2023, reaching $15,256,431[90]. - Total revenues for the nine months ended September 30, 2024 were $42,778,104, a 27.4% increase from $33,584,666 in the prior year[100]. - Plasma industry revenue rose by $377,822, or 3.4%, to $11,439,534, driven by the addition of 16 net new plasma centers and increased donations[91]. - Plasma industry revenue for the nine months ended September 30, 2024 increased by $2,644,590, while pharma industry revenue surged by $5,993,365[100]. - Pharma industry revenue surged by $2,248,618, or 219.1%, to $3,274,888, attributed to the launch of 32 new patient affordability programs[91]. Profitability - Gross profit for the three months ended September 30, 2024, increased by $2,141,196, or 33.8%, resulting in a gross margin of 55.5%[90][93]. - Gross profit for the nine months ended September 30, 2024 increased by $6,002,801, resulting in a gross margin of 53.8%[103]. - Net income for the period was $1,436,837, reflecting a 30.5% increase compared to the prior year, with a net margin of 9.42%[88]. - Net income for the three months ended September 30, 2024 was $1,436,837, an increase of $336,233 compared to the same period in 2023[98]. - Net income for the nine months ended September 30, 2024 was $2,443,035, an improvement of $1,606,717 compared to the prior year[108]. - Adjusted EBITDA for the nine months ended September 30, 2024, was $6,756,410, up 60.5% from $4,207,363 in 2023[113]. Operating Expenses - Operating expenses totaled $7,783,465, an increase of $2,041,779, or 35.6%, with selling, general and administrative expenses rising by 32.4%[88]. - Selling, general and administrative expenses for the three months ended September 30, 2024 increased by $1,521,335, primarily due to a $1,821,000 rise in compensation and benefits[94]. - Selling, general and administrative expenses for the nine months ended September 30, 2024 rose by $3,202,922, mainly due to a $4,012,000 increase in compensation and benefits[104]. - Depreciation and amortization expense for the three months ended September 30, 2024 increased by $520,444, driven by new software development costs and equipment purchases[95]. Cash Flow and Investments - Operating activities provided $8,633,922 of cash, an increase of 106.5% compared to $4,180,064 in the prior year[116]. - Cash used in investing activities was $7,087,867 for the nine months ended September 30, 2024, compared to $4,999,986 in 2023, reflecting increased investment in technology[117]. - Unrestricted cash as of September 30, 2024, was $10,293,207, an increase of 3.6% from $9,936,627 in the prior year[120]. - Financing activities used $331,695 in cash, primarily for the repurchase of 100,000 shares at an average price of $3.60 per share[118]. - The company financed operations through internally generated funds during the nine months ended September 30, 2024[115]. Future Outlook - The company plans to continue investing in technology improvements, sales and marketing, and regulatory compliance in 2024[89]. - Future product expansions are expected to include travel cards and expense reimbursement cards[78]. - The company continues to monitor bank relationships amid elevated interest rates and refinancing risks in commercial real estate[120]. Market Trends - The prepaid card market in the U.S. has seen significant growth, driven by improved technology and increased consumer adoption[84]. - The company manages all aspects of the prepaid card lifecycle, enhancing customer service with a fully staffed, in-house department[85]. Operational Performance - Income from operations for the three months ended September 30, 2024 was $689,849, an improvement of $99,417 compared to the prior year[96]. - Gross dollar volume loaded on cards was $456 million for the three months ended September 30, 2024, compared to $448 million in the same period of 2023[110]. - The increase in cash flows from operating activities was impacted by net income and non-cash adjustments for depreciation and amortization[116]. - Significant contractual cash requirements include ongoing payments for lease liabilities[119].

Core Insights - The article discusses the effectiveness of value investing as a strategy that has consistently performed well across various market conditions [2] - It highlights the Zacks Rank system and Style Scores as tools for identifying strong value stocks [3] Company Analysis - Paysign (PAYS) is currently rated 2 (Buy) with an A for Value, trading at a P/E ratio of 14.34, significantly lower than the industry average of 22.65 [4] - PAYS has a P/B ratio of 7.64, which is attractive compared to the industry average of 7.68, with its P/B fluctuating between 4.91 and 10.84 over the past year [5] - Western Union (WU) is also rated 2 (Buy) with a Value Score of A, trading at a Forward P/E ratio of 6.65 and a PEG ratio of 1.76, both favorable compared to the industry averages [6] - WU's P/B ratio stands at 9.32, higher than the industry average of 7.68, with its P/B ranging from 6.51 to 11.69 in the last 52 weeks [7] Investment Outlook - Both Paysign and Western Union are identified as likely undervalued stocks, supported by their strong earnings outlook, making them attractive options for value investors [8]

Group 1: Company Performance - Paysign, Inc. (PAYS) has achieved a year-to-date return of approximately 54.6%, significantly outperforming the average return of 14.2% for the Business Services sector [4] - The Zacks Consensus Estimate for PAYS' full-year earnings has increased by 10.5% over the past 90 days, indicating improved analyst sentiment and a stronger earnings outlook [3] - In comparison, another stock in the Business Services sector, Recruit Holdings Co., Ltd. (RCRRF), has returned 45.8% year-to-date [4] Group 2: Industry Context - Paysign, Inc. is part of the Financial Transaction Services industry, which consists of 42 companies and currently ranks 66 in the Zacks Industry Rank, with an average year-to-date gain of 12.3% [5] - The Business Services sector, which includes 317 individual stocks, is ranked 6 in the Zacks Sector Rank, indicating a relatively strong performance compared to other sectors [2] - Recruit Holdings Co., Ltd. operates within the Business - Information Services industry, which has 10 stocks and is ranked 89, with a year-to-date return of 16.5% [6]

Group 1 - Paysign, Inc. (PAYS) has shown a year-to-date return of 67.5%, significantly outperforming the average return of 10.9% in the Business Services sector [4] - The Zacks Consensus Estimate for PAYS' full-year earnings has increased by 10.5% over the past quarter, indicating improved analyst sentiment [4] - Paysign, Inc. is ranked 2 (Buy) in the Zacks Rank system, which focuses on earnings estimates and revisions [3] Group 2 - Paysign, Inc. is part of the Financial Transaction Services industry, which has an average return of 7.3% this year, further highlighting PAYS' strong performance [6] - Recruit Holdings Co., Ltd. (RCRRF) has also outperformed the Business Services sector with a return of 57% year-to-date and has a Zacks Rank of 1 (Strong Buy) [5] - The Business - Information Services industry, to which Recruit Holdings belongs, has seen a return of 12.2% this year, ranking 149 in the Zacks Industry Rank [6]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 001-38623 PAYSIGN, INC. (Exact name of registrant as specified in its charter) Nevada 95-4550154 (Sta ...

Exhibit 99.1 Earnings Release Paysign, Inc. Reports First Quarter 2024 Financial Results Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP metrics used by management to gauge the operating performance of the business – see reconciliation of net income to Adjusted EBITDA at the end of the press release. HENDERSON, Nev. – May 7, 2024 – (ACCESSWIRE) – Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and i ...

FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐TRANSITION PURSUANT TO UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-38623 PAYSIGN, INC. (Exact name of registrant as specified in its charter) Table of Contents Indicate by check mark whet ...